SCR-LIP-000329 · Claim · machine-readable JSON →

This review proposes a mechanistic rationale for gestrinone in lipedema—based on aromatase overexpression in lipedema adipose tissue, with gestrinone hypothesized to inhibit aromatase and block estrogen receptors and adipogenesis—but presents only in vitro cell-viability data (MTT in MDA-MB-231 and Huh7 lines) and no clinical trial demonstrating efficacy in lipedema patients.

Claim at a glance

Structured evidence, machine-compiled — not a verdict.

Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-05-31

Evidence over time

Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women — Renke et al. (2024) ✓ verified — contextual · review · 2024 · reading confidence: high
“Mecanismo proposto para o lipedema: na doença há superexpressão de aromatase no tecido adiposo, aumentando a conversão de androgênios em estrogênios e alimentando a fisiopatologia; a gestrinona inibiria a aromatase e bloquearia receptores estrogênicos.”
The article is a narrative/mechanistic review that proposes gestrinone use in lipedema as a new application, offering a speculative aromatase-inhibition rationale and only in vitro cell data; it provides no clinical efficacy evidence in lip

Populationwomen with lipedema (hypothetical/proposed)

Conditionlipedema

Exposuregestrinone (aromatase inhibitor, ER blocker)

Outcomemechanistic rationale; in vitro cell viability only

Scopeauto-ingested from Layer 1 surveillance

Auto-ingested single source; not yet human-reviewed.